These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20336785)

  • 21. Occurrence of breast cancer subtypes in adolescent and young adult women.
    Keegan TH; DeRouen MC; Press DJ; Kurian AW; Clarke CA
    Breast Cancer Res; 2012 Mar; 14(2):R55. PubMed ID: 22452927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
    JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
    Sengal AT; Haj-Mukhtar NS; Elhaj AM; Bedri S; Kantelhardt EJ; Mohamedani AA
    BMC Cancer; 2017 Dec; 17(1):804. PubMed ID: 29191181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study.
    Tao L; Gomez SL; Keegan TH; Kurian AW; Clarke CA
    Cancer Epidemiol Biomarkers Prev; 2015 Jul; 24(7):1039-45. PubMed ID: 25969506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
    BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
    Troester MA; Sun X; Allott EH; Geradts J; Cohen SM; Tse CK; Kirk EL; Thorne LB; Mathews M; Li Y; Hu Z; Robinson WR; Hoadley KA; Olopade OI; Reeder-Hayes KE; Earp HS; Olshan AF; Carey LA; Perou CM
    J Natl Cancer Inst; 2018 Feb; 110(2):176-82. PubMed ID: 28859290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
    Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
    Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Pooled Case-only Analysis of Reproductive Risk Factors and Breast Cancer Subtype Among Black Women in the Southeastern United States.
    Sanderson M; Pal T; Beeghly-Fadiel A; Fadden MK; Dujon SA; Clinton C; Jimenez C; Davis J; Fortune M; Thompson J; Benson K; Conley N; Reid S; Tezak A; Shu XO; Zheng W; Blot WJ; Lipworth L
    Cancer Epidemiol Biomarkers Prev; 2021 Jul; 30(7):1416-1423. PubMed ID: 33947654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016.
    Thomas A; Rhoads A; Suhl J; Conway KM; Hundley WG; McNally LR; Oleson J; Melin SA; Lynch CF; Romitti PA
    Clin Breast Cancer; 2020 Aug; 20(4):e410-e422. PubMed ID: 32278642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
    Bauer K; Parise C; Caggiano V
    BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
    Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
    J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
    Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
    Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence, mortality and receptor status of breast cancer in African Caribbean women: Data from the cancer registry of Guadeloupe.
    Deloumeaux J; Gaumond S; Bhakkan B; Manip M'Ebobisse N; Lafrance W; Lancelot P; Vacque D; Negesse Y; Diedhiou A; Kadhel P
    Cancer Epidemiol; 2017 Apr; 47():42-47. PubMed ID: 28119121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 status and disparities in luminal breast cancers.
    Holowatyj AN; Ruterbusch JJ; Ratnam M; Gorski DH; Cote ML
    Cancer Med; 2016 Aug; 5(8):2109-16. PubMed ID: 27250116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women.
    Keegan TH; Press DJ; Tao L; DeRouen MC; Kurian AW; Clarke CA; Gomez SL
    Breast Cancer Res; 2013; 15(5):R95. PubMed ID: 24131591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States).
    Tarone RE; Chu KC
    Cancer Causes Control; 2002 Feb; 13(1):7-14. PubMed ID: 11899120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
    Roseland ME; Schwartz K; Ruterbusch JJ; Lamerato L; Krajenta R; Booza J; Simon MS
    Breast Cancer Res Treat; 2017 Aug; 165(1):163-168. PubMed ID: 28547656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years.
    Kawai M; Malone KE; Tang MT; Li CI
    Cancer; 2014 May; 120(10):1548-56. PubMed ID: 24500704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.